Hettinger, K.

patient t-all group precursor b-all precursor b-all treatment mrd levels lymphoblastic leukemia leukemia level point mrd-based time points study lymphoblastic target childhood blood response relapse outcome prognostic mrd information mrd level intermediate-risk 5- year rfs prognostic value disease follow-up detection mrd-based risk groups mrd negativity analysis classification information difference children month value number pcr targets wbc count result rearrangement survival prednisone response diagnosis sample figure precursor b-all group van dongen jjm intermediate-risk group mrd-positive patients mrd-pcr protocol count frequency treatment outcome prednisone t-all group time point negativity 10 4 mrd-negative follow-up time points 3 mrd-pcr targets mrd-based intermediate-risk group t-cell sensitivity mrd-positive factor wolvers-tettero ilm lymphoblastic leukaemia mrd study t-all patients bm samples distribution prognostic factor volume